TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ).
NeuroScientific Biopharmaceuticals Limited reported a significant decrease in income from ordinary activities, down by 93.05% to $166,078 for the year ended 30 June 2025. The company also experienced a substantial increase in losses, with a 669.23% rise in loss after tax, amounting to $1,845,513. Despite these financial challenges, the company’s financial statements received an unqualified audit opinion, indicating no significant issues were found in their financial reporting. The company did not declare any dividends for the year, and the net tangible assets per ordinary share decreased from 3.50 cents to 2.22 cents, reflecting the financial strain the company is under.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development of therapeutic products targeting neurodegenerative conditions. The company is engaged in research and development to address unmet medical needs in neuroscience.
Average Trading Volume: 636,526
Technical Sentiment Signal: Buy
Current Market Cap: A$54.87M
For a thorough assessment of NSB stock, go to TipRanks’ Stock Analysis page.